Context Therapeutics Inc. (CNTX)
(Real Time Quote from BATS)
$2.17 USD
+0.05 (2.36%)
Updated Jul 22, 2024 01:10 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Context Therapeutics Inc. (CNTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.50 | $10.00 | $4.50 | 206.60% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Context Therapeutics Inc. comes to $6.50. The forecasts range from a low of $4.50 to a high of $10.00. The average price target represents an increase of 206.6% from the last closing price of $2.12.
Analyst Price Targets (3 )
Broker Rating
Context Therapeutics Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, three are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CNTX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/10/2024 | H.C. Wainwright & Co. | Emily Bodnar | Strong Buy | Strong Buy |
5/9/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 3 |
Average Target Price | $6.50 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 146 of 252 |
Current Quarter EPS Est: | -0.08 |